Bio-Rad Introduces its IH-1000 Blood Typing System for the U.S. Market
69th AACC Annual Scientific Meeting Press ProgramBio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its IH-1000 blood typing instrument along with approvals for a wide range of associated gel cards and reagents for the U.S. blood typing market. The system offers full automation and walk-away reliability, allowing laboratories to more efficiently manage their blood testing workload.